Back to results
US 12,553,041 B2Granted
Formulations and doses of pegylated uricase
AssigneeCartesian Therapeutics, Inc.
InventorsLloyd Johnston, Takashi Kei Kishimoto, Earl Sands, Werner Cautreels
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions and kits related to identification and/or treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.
Claims10
A method, comprising:
- sequentially co-administering to a subject having an anti-uricase antibody titer level below a threshold, a treatment dose comprising:
- 1) a composition comprising synthetic nanocarriers comprising an immunosuppressant and 2) a composition comprising uricase, wherein the uricase is pegsiticase, wherein the threshold is an anti-uricase antibody titer of 1080 or less, wherein the composition comprising synthetic nanocarriers comprising an immunosuppressant is administered prior to the composition comprising uricase, and wherein the concomitant administering is repeated with a 28 day treatment interval.
A method, comprising,
- identifying a subject having gout or a condition associated with gout, as having an anti-uricase antibody titer level below a threshold and treating the subject, wherein the threshold is an anti-uricase antibody titer of 1080 or less, wherein the treating occurs with a 28 day treatment interval and comprises sequentially co-administering to the subject 1) a composition comprising synthetic nanocarriers comprising an immunosuppressant prior to 2) a composition comprising uricase, wherein the uricase is pegsiticase.
Dependencies are inferred from the claim text.